BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31751580)

  • 21. Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.
    Zhang S; Meng T; Liu J; Zhang X; Zhang J
    Medicine (Baltimore); 2015 Jan; 94(4):e445. PubMed ID: 25634181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
    Lenčová-Popelová O; Jirkovský E; Jansová H; Jirkovská-Vávrová A; Vostatková-Tichotová L; Mazurová Y; Adamcová M; Chládek J; Hroch M; Pokorná Z; Geršl V; Šimůnek T; Štěrba M
    J Mol Cell Cardiol; 2016 Feb; 91():92-103. PubMed ID: 26724189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
    Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
    PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats.
    Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA
    Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attenuation of doxorubicin-induced cardiotoxicity in a human in vitro cardiac model by the induction of the NRF-2 pathway.
    Tomlinson L; Lu ZQ; Bentley RA; Colley HE; Murdoch C; Webb SD; Cross MJ; Copple IM; Sharma P
    Biomed Pharmacother; 2019 Apr; 112():108637. PubMed ID: 30798127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
    Damiani RM; Moura DJ; Viau CM; Caceres RA; Henriques JAP; Saffi J
    Arch Toxicol; 2016 Sep; 90(9):2063-2076. PubMed ID: 27342245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
    Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
    Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleolin protects against doxorubicin-induced cardiotoxicity via upregulating microRNA-21.
    Sun H; Tong Z; Fang Y; Jiang B; Liang P; Tang Y; Li Y; Wu Y; Xiao X
    J Cell Physiol; 2018 Dec; 233(12):9516-9525. PubMed ID: 29968904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity.
    Lee KH; Cho H; Lee S; Woo JS; Cho BH; Kang JH; Jeong YM; Cheng XW; Kim W
    Int J Cardiol; 2017 Apr; 232():40-47. PubMed ID: 28159361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity.
    Antoniak S; Tatsumi K; Schmedes CM; Grover SP; Pawlinski R; Mackman N
    J Mol Cell Cardiol; 2018 Sep; 122():80-87. PubMed ID: 30098988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C1qTNF-related protein 1 attenuates doxorubicin-induced cardiac injury via activation of AKT.
    Chen H; Gao L; Huang Z; Liu Y; Guo S; Xing J; Meng Z; Liang C; Li Y; Yao R; Li L; Zhang Y; Gu H; Liu Y
    Life Sci; 2018 Aug; 207():492-498. PubMed ID: 29964055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice.
    Vijay V; Moland CL; Han T; Fuscoe JC; Lee T; Herman EH; Jenkins GR; Lewis SM; Cummings CA; Gao Y; Cao Z; Yu LR; Desai VG
    Toxicol Appl Pharmacol; 2016 Mar; 295():68-84. PubMed ID: 26873546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization.
    Mody H; Vaidya TR; Ait-Oudhia S
    Sci Rep; 2023 Feb; 13(1):3100. PubMed ID: 36813809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (-)-Epigallocatechin-3-gallate alleviates doxorubicin-induced cardiotoxicity in sarcoma 180 tumor-bearing mice.
    Yao YF; Liu X; Li WJ; Shi ZW; Yan YX; Wang LF; Chen M; Xie MY
    Life Sci; 2017 Jul; 180():151-159. PubMed ID: 27956351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paradoxically, iron overload does not potentiate doxorubicin-induced cardiotoxicity in vitro in cardiomyocytes and in vivo in mice.
    Guenancia C; Li N; Hachet O; Rigal E; Cottin Y; Dutartre P; Rochette L; Vergely C
    Toxicol Appl Pharmacol; 2015 Apr; 284(2):152-62. PubMed ID: 25711856
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F
    Desai VG; Lee T; Moland CL; Vijay V; Han T; Lewis SM; Herman EH; Fuscoe JC
    Toxicol Appl Pharmacol; 2019 Jan; 363():164-173. PubMed ID: 30517846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
    Sun X; Zhou Z; Kang YJ
    Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C1qTNF-related protein-6 protects against doxorubicin-induced cardiac injury.
    Zheng WF; Zhang SY; Ma HF; Chang XW; Wang H
    J Cell Biochem; 2019 Jun; 120(6):10748-10755. PubMed ID: 30719766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
    Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
    BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Lack of Synergy between Carvedilol and the Preventive Effect of Dexrazoxane in the Model of Chronic Anthracycline-Induced Cardiomyopathy.
    Szponar J; Ciechanski E; Ostrowska-Lesko M; Gorska A; Tchorz M; Dabrowska A; Dudka J; Murias M; Kowalczyk M; Korga-Plewko A; Mandziuk S
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.